Long-term safety and efficacy of sutimlimab for chronic ITP

Catherine Broome, MD, Georgetown University Hospital, Washington, D.C, discusses the interim results of a Phase I trial (NCT03275454) investigating sutimlimab (BIVV009) for patients with chronic immune thrombocytopenia (ITP). Sutimlimab is a humanized monoclonal antibody which selectively inhibits activation of the classical complement pathway by binding C1s. The study found that sutimlimab therapy achieved a rapid and durable response in platelet count in patients with chronic ITP who had inadequate responses to prior therapies. The response was sustained after more than one year of therapy, with an acceptable safety profile. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.